Australia markets closed

Poxel S.A. (PXXLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.10000.0000 (0.00%)
As of 11:17AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.1000
Open2.1000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.1000 - 2.1000
52-week range2.1000 - 9.2600
Volume500
Avg. volume5
Market cap52.68M
Beta (5Y monthly)1.69
PE ratio (TTM)N/A
EPS (TTM)-0.8710
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Poxel Announces Extended Cash Runway with Debt Restructuring Agreement and Equity-linked Financing Facility

    LYON, France, August 08, 2022--POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today that is has entered into (1) an agreement with IPF to restructure its existing debt facility and (2) an equity-linked financing for up to EUR 6 million with IRIS. On that basis, the Company expect

  • Business Wire

    Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2022

    LYON, France, August 08, 2022--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the second quarter and first half of 2022.

  • Business Wire

    Poxel Announces the Publication of Two Preclinical Articles on X-Linked Adrenoleukodystrophy for PXL065 and PXL770

    LYON, France, July 05, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of two preclinical articles on X-Linked Adrenoleukodystrophy (ALD) for PXL065 and PXL770. These molecules have separate and distinct mechanisms of action: PXL065 is a novel, propriet